JP7659271B2 - 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター - Google Patents

導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター Download PDF

Info

Publication number
JP7659271B2
JP7659271B2 JP2021557657A JP2021557657A JP7659271B2 JP 7659271 B2 JP7659271 B2 JP 7659271B2 JP 2021557657 A JP2021557657 A JP 2021557657A JP 2021557657 A JP2021557657 A JP 2021557657A JP 7659271 B2 JP7659271 B2 JP 7659271B2
Authority
JP
Japan
Prior art keywords
aav
cell
aav9
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527917A5 (cg-RX-API-DMAC7.html
JP2022527917A (ja
Inventor
エー. マグワイア,ケイシー
マリー ハドリー,エロイーズ
ハンロン,キリアン,エス.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2022527917A publication Critical patent/JP2022527917A/ja
Publication of JP2022527917A5 publication Critical patent/JP2022527917A5/ja
Priority to JP2025044435A priority Critical patent/JP2025098107A/ja
Application granted granted Critical
Publication of JP7659271B2 publication Critical patent/JP7659271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021557657A 2019-03-28 2020-03-30 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター Active JP7659271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044435A JP2025098107A (ja) 2019-03-28 2025-03-19 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825703P 2019-03-28 2019-03-28
US62/825,703 2019-03-28
PCT/US2020/025720 WO2020198737A1 (en) 2019-03-28 2020-03-30 Engineered adeno-associated (aav) vectors for transgene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044435A Division JP2025098107A (ja) 2019-03-28 2025-03-19 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター

Publications (3)

Publication Number Publication Date
JP2022527917A JP2022527917A (ja) 2022-06-07
JP2022527917A5 JP2022527917A5 (cg-RX-API-DMAC7.html) 2023-04-06
JP7659271B2 true JP7659271B2 (ja) 2025-04-09

Family

ID=72609527

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557657A Active JP7659271B2 (ja) 2019-03-28 2020-03-30 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター
JP2025044435A Pending JP2025098107A (ja) 2019-03-28 2025-03-19 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044435A Pending JP2025098107A (ja) 2019-03-28 2025-03-19 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター

Country Status (12)

Country Link
US (1) US20220195458A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947422A4 (cg-RX-API-DMAC7.html)
JP (2) JP7659271B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260036045A (cg-RX-API-DMAC7.html)
CN (1) CN113874387B (cg-RX-API-DMAC7.html)
AU (2) AU2020248116B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135292A1 (cg-RX-API-DMAC7.html)
IL (1) IL286725A (cg-RX-API-DMAC7.html)
MX (1) MX2021011701A (cg-RX-API-DMAC7.html)
SG (1) SG11202110165XA (cg-RX-API-DMAC7.html)
WO (1) WO2020198737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200016A1 (en) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
US11149256B2 (en) 2018-09-26 2021-10-19 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3959324B1 (en) 2019-04-26 2025-09-17 President and Fellows of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
AU2020366531A1 (en) * 2019-10-18 2022-05-26 Research Institute At Nationwide Children's Hospital Gene therapy targeting cochlear cells
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
US20240075167A1 (en) * 2021-02-03 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Method of gene delivery to retinal astrocytes
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
CN114606264B (zh) * 2022-03-22 2025-08-26 三峡大学 一种用于神经系统药物递送的aav病毒载体
WO2024054864A1 (en) 2022-09-06 2024-03-14 Tenaya Therapeutics, Inc. Cardioprotective heart disease therapies
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
EP4695396A1 (en) 2023-04-10 2026-02-18 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
WO2024220545A2 (en) * 2023-04-17 2024-10-24 The General Hospital Corporation Aav capsids for on-target delivery to spinal cord
EP4698555A1 (en) * 2023-04-18 2026-02-25 uniQure biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2018189244A1 (en) 2017-04-11 2018-10-18 Ruprecht-Karls-Universität Heidelberg Adeno-associated virus library

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
ES2547381T3 (es) * 2004-04-09 2015-10-05 Monsanto Technology, Llc Composiciones y procedimientos de control de infestaciones de insectos en plantas
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
NZ716102A (en) * 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3564379A1 (en) * 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
US10307492B2 (en) * 2014-03-11 2019-06-04 Wayne State University Modified MGLUR6 promoter and methods of use
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
GB2545763A (en) * 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
JP6994018B2 (ja) * 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
US11512327B2 (en) * 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020001997A (es) * 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.
CA3092107A1 (en) * 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
CN109207520B (zh) * 2018-09-25 2022-05-10 北京锦篮基因科技有限公司 Leber遗传性视神经病变的基因药物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136536A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2018189244A1 (en) 2017-04-11 2018-10-18 Ruprecht-Karls-Universität Heidelberg Adeno-associated virus library

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Biotechnology,2016年,34,204-209

Also Published As

Publication number Publication date
US20220195458A1 (en) 2022-06-23
AU2026201434A1 (en) 2026-03-19
EP3947422A4 (en) 2023-05-17
KR102934700B1 (ko) 2026-03-09
WO2020198737A1 (en) 2020-10-01
BR112021019436A2 (pt) 2021-12-07
AU2020248116A1 (en) 2021-10-14
MX2021011701A (es) 2021-12-10
CA3135292A1 (en) 2020-10-01
KR20260036045A (ko) 2026-03-13
JP2025098107A (ja) 2025-07-01
KR20210143869A (ko) 2021-11-29
IL286725A (en) 2021-12-01
CN113874387B (zh) 2025-01-07
AU2020248116B2 (en) 2025-12-04
EP3947422A1 (en) 2022-02-09
JP2022527917A (ja) 2022-06-07
CN113874387A (zh) 2021-12-31
SG11202110165XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
KR102934700B1 (ko) 트랜스진 발현을 위한 조작된 아데노-연관 (aav) 벡터
US20240209394A1 (en) AAV Capsids and Uses Thereof
RU2727672C2 (ru) Нацеливающие пептиды для направленной доставки аденоассоциированных вирусов (aav)
CN110546257B (zh) 用于增强基因表达的组合物和方法
AU2020375947B2 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
US12252520B2 (en) Myosin 15 promoters and uses thereof
CN120843603A (zh) 用于跨血脑屏障递送试剂的方法和组合物
AU2008216018B2 (en) Mitochondrial nucleic acid delivery systems
KR20200120649A (ko) 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
CN109154002B (zh) 用于治疗显性视网膜色素变性的aav载体
KR20220066225A (ko) 선택적 유전자 조절을 위한 조성물 및 방법
JP2024517843A (ja) ステレオシリン二重ベクター系を使用して感音性難聴を治療するための組成物及び方法
WO2021091950A1 (en) Vestibular supporting cell promoters and uses thereof
CN112852881B (zh) 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法
RU2839774C2 (ru) Сконструированные аденоассоциированные (aav) векторы для экспрессии трансгена
Fehrman Feasibility of Large Transgene Delivery to the Mouse Retina: Eyeing the Potential for Gene Therapy Applications
WO2024220545A2 (en) Aav capsids for on-target delivery to spinal cord
WO2025015092A1 (en) Novel cam-kinase promoter and uses thereof for treating nervous system disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250319

R150 Certificate of patent or registration of utility model

Ref document number: 7659271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150